Relevant bibliographies by topics / Aminobisphosphonate

Academic literature on the topic 'Aminobisphosphonate'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Aminobisphosphonate.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Aminobisphosphonate"

1

Das, Hiranmoy, Lisheng Wang, Arati Kamath, and Jack F. Bukowski. "Vγ2Vδ2 T-cell receptor–mediated recognition of aminobisphosphonates." Blood 98, no. 5 (September 1, 2001): 1616–18. http://dx.doi.org/10.1182/blood.v98.5.1616.

Full text
Abstract:
Aminobisphosphonates, potent derivatives of bisphosphonates, are frequently used for the treatment of conditions such as osteoporosis and bone metastases that are characterized by excessive osteoclastic bone resorption. Using T-cell receptor (TCR) transfer studies, we show that recognition of antigenic aminobisphosphonates that are known to stimulate human γδ T cells in vitro and in vivo (potency: risedronate > alendronate > pamidronate) requires expression of the Vγ2Vδ2 TCR and is thus Vγ2Vδ2 TCR–dependent. Myeloma cells or monocytes pulsed with risedronate and then washed rendered these target cells sensitive to lysis by a Vγ2Vδ2 T-cell clone or cell line. These results suggest that Vγ2Vδ2 TCR–dependent recognition leading to direct cytolysis of aminobisphosphonate-sensitized osteoclast or tumor targets may be a mechanism whereby aminobisphosphonate treatment of cancers metastatic to bone decreases osteoclastic activity and tumor burden and also may account for the decreased osteoclastic activity associated with successful treatment of osteoporosis.
APA, Harvard, Vancouver, ISO, and other styles
2

Endo, Yasuo, Masahiko Shibazaki, Kouji Yamaguchi, Masanori Nakamura, and Hiroshi Kosugi. "Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate." British Journal of Pharmacology 126, no. 4 (February 1999): 903–10. http://dx.doi.org/10.1038/sj.bjp.0702367.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kantoci, Darko, J. Kane Denike, and William J. Wechter. "Synthesis of Aminobisphosphonate." Synthetic Communications 26, no. 10 (May 1996): 2037–43. http://dx.doi.org/10.1080/00397919608003560.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

KANTOCI, D., J. K. DENIKE, and W. J. WECHTER. "ChemInform Abstract: Synthesis of Aminobisphosphonate." ChemInform 27, no. 34 (August 5, 2010): no. http://dx.doi.org/10.1002/chin.199634177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cairo, Cristiana, Bertrand Sagnia, Giulia Cappelli, Rose Leke, Robert Leke, Vittorio Colizzi, and C. Pauza. "Repertoire selection and effector functions of neonatal γδ T cells (85.12)." Journal of Immunology 184, no. 1_Supplement (April 1, 2010): 85.12. http://dx.doi.org/10.4049/jimmunol.184.supp.85.12.

Full text
Abstract:
Abstract The neonatal T cell repertoire includes a low frequency of Vγ2Vδ2 T cells. This population is poorly reactive to phosphoantigens or aminobisphosphonates, compared to the adult repertoire in blood. The neonatal Vδ2 cell population also shows a reduced proportion of Vγ2-Jγ1.2 rearrangements; this TCR chain combines with the Vδ2 to endow phosphoantigen responsiveness. We are interested in how the neonatal repertoire is selected to produce the dominant Vγ2-Jγ1.2 rearrangement seen in adults. IL-15 did not improve responses to stimulation, but improved survival. Both IL-2 and IL-15 up-regulated NK receptors and perforin production, although IL-2 preferentially down-regulated CD27 expression, that may be linked to the development of cytotoxicity. Curiously, aminobisphosphonate stimulation in a single round selected a Vγ2 repertoire similar to adults. Thus, neonatal γδ T cells found in cord blood are an attractive model for understanding the genesis of cytotoxic T cells lineages.
APA, Harvard, Vancouver, ISO, and other styles
6

Kuźnik, Anna, Dominika Kozicka, Wioleta Hawranek, Karolina Socha, and Karol Erfurt. "One-Pot and Catalyst-Free Transformation of N-Protected 1-Amino-1-Ethoxyalkylphosphonates into Bisphosphonic Analogs of Protein and Non-Protein α-Amino Acids." Molecules 27, no. 11 (June 2, 2022): 3571. http://dx.doi.org/10.3390/molecules27113571.

Full text
Abstract:
Herein, we describe the development of one-pot transformation of α-ethoxy derivatives of phosphorus analogs of protein and non-protein α-amino acids into biologically important N-protected 1-aminobisphosphonates. The proposed strategy, based on the three-component reaction of 1-(N-acylamino)-1-ethoxyphosphonates with triphenylphosphonium tetrafluoroborate and triethyl phosphite, facilitates good to excellent yields under mild reaction conditions. The course of the reaction was monitored by 31P NMR spectroscopy, allowing the identification of probable intermediate species, thus making it possible to propose a reaction mechanism. In most cases, there is no need to use a catalyst to provide transformation efficiency, which increases its attractiveness both in economic and ecological terms. Furthermore, we demonstrate that the one-pot procedure can be successfully applied for the synthesis of structurally diverse N-protected bisphosphonic analogs of α-amino acids. As shown, the indirect formation of the corresponding phosphonium salt as a reactive intermediate during the conversion of 1-(N-acylamino)-1-ethoxyphosphonate into a 1-aminobisphosphonate derivative is a crucial component of the developed methodology.
APA, Harvard, Vancouver, ISO, and other styles
7

Meraviglia, Serena, Carmela La Mendola, Valentina Orlando, Francesco Scarpa, Giuseppe Cicero, and Francesco Dieli. "Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies." Oncology Reviews 4, no. 4 (December 14, 2011): 211. http://dx.doi.org/10.4081/oncol.2010.211.

Full text
Abstract:
The potent anti-tumor activities of γδ T cells, their ability to produce pro-inflammatory cytokines, and their strong cytolytic activity have prompted the development of protocols in which γδ agonists or ex vivo-expanded γδ cells are administered to tumor patients. γδ T cells can be selectively activated by either synthetic phosphoantigens or by drugs that enhance their accumulation into stressed cells as aminobisphosphonates, thus offering new avenues for the development of γδ T cell-based immunotherapies. The recent development of small drugs selectively activating Vγ9Vδ2 T lymphocytes, which upregulate the endogenous phosphoantigens, has enabled the investigators to design the experimental approaches of cancer immunotherapies; several ongoing phase I and II clinical trials are focused on the role of the direct bioactivity of drugs and of adoptive cell therapies involving phosphoantigen- or aminobisphosphonate-activated Vγ9Vδ2 T lymphocytes in humans. In this review, we focus on the recent advances in the activation/expansion of γδ T cells in vitro and in vivo that may represent a promising target for the design of novel and highly innovative immunotherapy in patients with hematologic malignancies.<br />
APA, Harvard, Vancouver, ISO, and other styles
8

NAKASHIMA, Mitsuyoshi, Mitsutaka KANAMARU, and Norihiro TAKENAGA. "Phase I Study of Alendronate, a New Aminobisphosphonate." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 26, no. 2 (1995): 475–89. http://dx.doi.org/10.3999/jscpt.26.475.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Liu, Chia-Yuan, Po-Sheng Yang, Shih-Ping Cheng, Yu-Chuen Huang, Jie-Jen Lee, Chun-Chuan Ko, Hui-Ru Shieh, and Yu-Jen Chen. "Zoledronic acid, an aminobisphosphonate, prolongs survival of skin allografts." Clinical & Investigative Medicine 35, no. 4 (August 4, 2012): 165. http://dx.doi.org/10.25011/cim.v35i4.17144.

Full text
Abstract:
Purpose: Zoledronic acid (ZOL), an effective nitrogen-containing bisphosphonate used to prevent excessive bone loss in clinical practice, has been shown to affect the development of dendritic cells by redirecting differentiation toward a state of atypical maturation. The study was aimed to examine whether ZOL can reduce acute rejection of skin allografts. Methods: A skin transplantation model using C57BL/6 to BALB/c mice was used. ZOL was injected intraperitoneally into transplant recipients post-surgically. Graft survival, body weight, leukocyte count, hepatic and renal functions were assessed. Results: ZOL treatment significantly prolonged skin allograft survival in mice. In terms of toxicity, there were no significant differences in body weight, leukocyte count, plasma alanine aminotransferase or creatinine levels between the ZOL-treated and control groups. Histopathology showed that the loss of skin integrity seen in control group was prevented by ZOL treatment. In draining lymph nodes and spleen, the number and clustering extent of mononuclear cells were markedly declined by ZOL treatment. The plasma IL-6 levels were reduced by treatment of ZOL. Conclusion: ZOL can prolong skin allograft survival without major toxicity.
APA, Harvard, Vancouver, ISO, and other styles
10

Moon, Myung-Sang, Ki-Tae Kwon, Chang-Won Ha, Sung-Soo Kim, Sung Sim Kim, and Hanlim Moon. "BONE HISTOLOGY OF PATIENTS WITH ALENDRONATE-MEDIATED FRACTURED BONE — A NEW ENTITY OF ATYPICAL OSTEOMALACIA." Journal of Musculoskeletal Research 17, no. 03 (September 2014): 1450011. http://dx.doi.org/10.1142/s0218957714500110.

Full text
Abstract:
Based on the pharmaco-physiology of the aminobisphosphonates, it could be speculated that bisphosphonates could induce not only the osteopetrotic bone disease because of their selective suppression of osteoclastic activity, but also could affect directly or indirectly the endocrine system, local factors, and also the bone metabolic turnover. Consequently, the bone fragility could be rather produced by long-term aminobisphosphonate therapy. Bisphosphonate-mediated bone disease was labeled by Odvina et al. in 2005 [Odvina CV, Zerwerth JE, Rao DS et al. Severely suppressed bone turnover; a potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294–1301, 2005.] as the "severely suppressed bone turnover (SSBT)" on the metabolic turnover basis. However, such definition could contain various drug-induced bone diseases, and did not indicate any particular condition, induced by the bisphosphonate. The term "SSBT" is thought not solely to be based on its histology, and seems rather a clinical term applicable to the various drug-induced bone diseases. Therefore, the current authors attempted to characterize the bisphosphonate-mediated bone disease on the basis of the combined image and histological studies, and finally concluded that the prolonged bisphosphonate therapy could produce an atypical osteomalacic bone disease. (osteosclerosis of osteomalacia) which leads to fragility fracture. It is puzzling as to why malacia rather than petrosis develops in the skeleton.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Aminobisphosphonate"

1

Daguzan, Charline. "Analyse des propriétés antivirales des lymphocytes T Vgamma9Vdelta2 humains : potentiel immuno-thérapeutique au cours des infections par le cytomégalovirus humain." Thesis, Toulouse 3, 2015. http://www.theses.fr/2015TOU30241/document.

Full text
Abstract:
Le traitement de cellules par des aminobisphosphonates (ABP) induit une accumulation intracellulaire de molécules activatrices des lymphocytes T Vy9Vd2 (IPP, ApppI). Alors que ces lymphocytes ne semblent pas naturellement activés lors d'une infection par le cytomégalovirus humain (HCMV), le laboratoire a mis en évidence l'existence d'une action synergique entre le HCMV et les ABP sur leur activation. Ma thèse a eu pour objectif d'analyser le mécanisme de cette synergie et d'évaluer le potentiel immuno-thérapeutique des ABP dans le cadre d'une infection HCMV. Nous avons montré qu'après sensibilisation par des ABP in vitro, des cellules infectées sont fortement activatrices des T Vy9Vd2. Les fibroblastes traités par des ABP activent la production d'IFN-y par les T Vy9Vd2 mais pas la production de TNF. L'infection de ces fibroblastes par le HCMV induit une augmentation de la production d'IFN-y et stimule la production de TNF par des T Vy9Vd2. Cette activation a été observée avec des lymphocytes T Vy9Vd2 établis en lignées cellulaires mais aussi avec des cellules Vy9Vd2 isolées directement de sang périphérique. De plus, cette augmentation de production de cytokines est observée avec différentes souches virales (souche de laboratoire et isolats cliniques) et différents types cellulaires permissifs pour HCMV. Nous avons également montré que l'infection par le HCMV entraine une surproduction d'IPP et d'ApppI dans les cellules cibles traitées aux ABP, ce qui explique en partie l'augmentation de la sécrétion de cytokines par les T Vy9Vd2. Enfin, nous avons mis en évidence que ces T Vy9Vd2 sont capables de limiter la réplication et la production virale suite à un traitement par des ABP, tout en préservant les cellules non infectées. Selon nos études, cette activité antivirale implique la production des cytokines IFN-y et TNF et non l'activité cytotoxique des T Vy9Vd2. Par conséquent, mes travaux de thèse fournissent une preuve de concept pour une application thérapeutique des ABP dans le cadre d'une infection par le HCMV
Aminobisphosphonates (ABP) treatment of cells induces intracellular accumulation of molecules (IPP, ApppI) which stimulate human Vy9Vd2 T cells. Although these lymphocytes do not appear naturally activated during human cytomegalovirus (HCMV) infection, the laboratory demonstrated a synergistic effect of HCMV and ABP on Vy9Vd2 T cell activation. My PhD thesis aimed to analyze the mechanism of this synergy and evaluate the immunotherapeutic potential of ABP in the context of HCMV infection. After ABP treatment of cells in vitro, we showed that HCMV-infected cells strongly activated Vy9Vd2 T cells. ABP-treated fibroblasts activate Vy9Vd2 T cells to produce IFN-y but not TNF. The HCMV infection of these fibroblasts stimulates TNF secretion and an increased production of IFN-y, indicating that Vy9Vd2 cells can sense HCMV infection. Increased cytokine production was observed with Vy9Vd2 T cell lines and "fresh" Vy9Vd2 directly isolated of blood. Moreover, Vy9Vd2 T cell activation was observed with most HCMV strains (laboratory strains or clinical isolates) and different HCMV-permissive cells. We also showed that HCMV infection induces an overproduction of IPP and ApppI in ABP-treated cells, which explains in part the increased cytokine production by Vy9Vd2 T cells. At last, we demonstrated the capacity of Vy9Vd2 T cells to limit viral replication and production after ABP treatment while preserving uninfected cells. Our experiments indicate that this antiviral activity involves IFN-y and TNF secretion by Vy9Vd2 T cells but not their cytotoxicity activity. Consequently, my work provides a proof of concept of the therapeutic potential of ABP in the context of HCMV infection
APA, Harvard, Vancouver, ISO, and other styles
2

Gundermann, Stefan [Verfasser], and Volker [Gutachter] Kunzmann. "Untersuchungen zur natürlichen und Aminobisphosphonat-induzierten antileukämischen Aktivität von humanen allogenen Vγ9Vδ2 T-Zellen gegenüber akuter myeloischer Leukämie / Stefan Gundermann. Gutachter: Volker Kunzmann." Würzburg : Universität Würzburg, 2014. http://d-nb.info/1102828513/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gebhard, Harry Heinz [Verfasser]. "Effekt von selektivem Cyclooxygenase 2-Inhibitor Celecoxib und Aminobisphosphonat Ibandronat auf die Entzündungsreaktion und die synoviale Mikrozirkulation in der Antigen-induzierten Arthritis der Maus / Harry Heinz Gebhard." München : Verlag Dr. Hut, 2019. http://d-nb.info/1181515483/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zysk, Aneta. "Adoptive transfer of ex vivo expanded gamma delta T cells targeting osteolytic cancer in the bone." Thesis, 2017. http://hdl.handle.net/2440/119272.

Full text
Abstract:
Bone metastases occur in more than 75% of patients with advanced breast cancer. Cancer in bone is associated with bone destruction and is responsible for high levels of morbidity and mortality but is notoriously difficult to treat. Bone destruction is also the primary cause of morbidity in patients with primary bone cancer, such as osteosarcoma, with metastatic spread to the lungs correlating with poor survival. Therefore, clearly new therapies are desperately required to target cancers in the bone. This study explored the therapeutic potential of gamma delta (Vγ9Vδ2) T cell based adoptive transfer using animal models of osteolytic breast cancer and osteosarcoma. Cytotoxic Vγ9Vδ2 T cells were expanded ex vivo from peripheral blood using IL-2 and zoledronic acid (ZOL). In vitro, expanded Vγ9Vδ2 T cells were cytotoxic against a panel of breast cancer and osteosarcoma cell lines and pre-treatment with ZOL sensitised all cancer cells to rapid killing by Vγ9Vδ2 T cells. Adoptive transfer of fluorescently labelled ex vivo expanded Vγ9Vδ2 T cells into NOD/SCID mice localised to cancer lesions in bone. Multiple infusions of Vγ9Vδ2 T cells reduced breast cancer growth, but had no effect on osteosarcoma growth in the bone marrow. However, in both cases, ZOL pre-treatment potentiated the anti-cancer efficacy of Vγ9Vδ2 T cells in bone, protected the bone from cancer-induced osteolysis and decreased the incidence of pulmonary metastases. Collectively these studies suggest this treatment regimen to be an effective immunotherapeutic approach for the treatment of primary and metastatic bone cancers.
Thesis (Ph.D.) -- University of Adelaide, Adelaide Medical School, 2017
APA, Harvard, Vancouver, ISO, and other styles
5

Gundermann, Stefan. "Untersuchungen zur natürlichen und Aminobisphosphonat-induzierten antileukämischen Aktivität von humanen allogenen Vγ9Vδ2 T-Zellen gegenüber akuter myeloischer Leukämie." Doctoral thesis, 2014. https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-105425.

Full text
Abstract:
Adoptive Immuntherapien mit allogenen Vγ9Vδ2 T-Zellen sind eine vielversprechende therapeutische Behandlungsstrategie für eine Reihe von hämatologischen Erkrankungen. Im Gegensatz zu konventionellen αβ T-Zellen sind allogene Vγ9Vδ2 T-Zellen in der Lage Tumorzellen MHC-unabhängig zu lysieren ohne eine „graft-versus-host“ (GvH)-Reaktion zu induzieren. In der vorliegenden Arbeit wurde die in vitro Antileukämieantwort von HLA-inkompatiblen Vγ9Vδ2 T-Zellen gegenüber primären AML-Zellen systematisch untersucht. Die antileukämische Aktivität von Vγ9Vδ2 T-Zellen wurde in einem durchflusszytometrisch-basierten Zytotoxizitätsassay bestimmt und mit der Oberflächenexpression Killer-aktivierender und inhibierender Liganden (z.B. NKG2D- und DNAM1-Liganden), KIR-Liganden-Inkompatibilität zwischen Patienten und Spender und intrinsischen AML-Merkmalen (Zytogenetik, Immunphänotyp, Chemotherapiesensitivität der AML-Blasten) korreliert. Die beobachtete Zytotoxizität war deutlich heterogen (2.91 %- 56.26 %). 37 % der AML-Zellen waren primär empfindlich bzw. 63 % refraktär gegenüber Vγ9Vδ2 T-Zellen. Die Suszeptibilität der AML-Blasten gegenüber Vγ9Vδ2 T-Zellen korrelierte mit der Oberflächenexpression von ULBP1 und CD112 und monozytärer bzw. monoblastischer AML-Differenzierung. Die antileukämische Aktivität von Vγ9Vδ2 T-Zellen war dagegen unabhängig vom KIR-Liganden-Status zwischen Patienten und Spendern, zytogenetischem Risiko und Chemotherapiesensitivität der AML-Blasten. Die Vorbehandlung der Leukämiezellen mit Aminobisphosphonaten (Zoledronat) führte, insbesondere bei myelo-monozytär-differenzierten AML-Zellen, zu einer signifikanten dosisabhängigen Steigerung der antileukämischen Aktivität von Vγ9Vδ2 T-Zellen. Die Empfindlichkeit von myelo-monozytär-differenzierten Leukämiezellen gegenüber Zoledronat bzw. Vγ9Vδ2 T-Zellen korrelierte mit der Aktivität des Mevalonatmetabolismus. Dagegen zeigte die Mehrheit myeloblastischer AML-Blasten keine natürliche und nur geringe Aminobisphosphonat-induzierte Suszeptibilität gegenüber Vγ9Vδ2 T-Zellen. In der vorliegenden Arbeit konnten biologische Merkmale von AML-Blasten identifiziert werden, die mit der Antileukämieantwort von Vγ9Vδ2 T-Zellen korrelieren
Allogeneic γδ T cells are attractive candidates for immunotherapy of hematological malignancies due to their intrinsic ability to provide MHC-unrestricted antitumor activity without inducing graft-versus-host disease (GvHD). The present thesis evaluated the antileukemic capacity of allogeneic γδ T cells against primary acute myeloid leukemia (AML) in order to determine clinical factors that might predict the susceptibility of AML cells to γδ T cells. Leukemic blasts were obtained from 19 newly diagnosed AML patients. In vitro alloreactivity of Vγ9Vδ2 T cells lines derived from TCR αβ depleted leukapheresis products was evaluated by flow-cytometer based cytotoxicity assays. Marked differences of γδ T cell mediated cytotoxicity against AML blasts. 7 of 19 AML samples (37%) were intrinsically susceptible to allogeneic γδ T cells. Pretreatment of primary AML blasts with nitrogen-containing bisphosphonates (NBP) significantly induced (p<0.01) γδ T cell cytotoxicity in a dose-dependent manner in 32% of AML samples. The remaining 31% AML samples were consistently refractory to γδ T cell immunotargeting. ULBP1 surface expression and myelo-monocytic differentiation of AML cells correlated with innate and NBP-induced killing of AML cells by allogeneic γδ T cells, whereas KIR-ligand mismatch status, cytogenetic risk profiles and response to induction chemotherapy showed no correlation with the susceptibility of primary AML blast to γδ T cells. This study identifies relevant subsets of AML as attractive targets for upcoming γδ T cell based adoptive immunotherapies
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Aminobisphosphonate"

1

"Aminobisphosphonate." In Encyclopedia of Pain, 116. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-28753-4_200098.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Aminobisphosphonate"

1

Zakeri, Nekisa, Andrew Hall, Leo Swadling, Laura J. Pallett, Nathalie M. Schmidt, Mariana O. Diniz, Stephanie Kucykowicz, et al. "O06 Aminobisphosphonates enhance liver-resident gamma delta T cells for efficient targeting of hepatocellular carcinoma." In Abstracts of the British Association for the Study of the Liver Annual Meeting, 22–24 November 2021. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2021. http://dx.doi.org/10.1136/gutjnl-2021-basl.6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Giollo, A., F. Bettili, F. Ghellere, O. Viapiana, L. Idolazzi, D. Gatti, and M. Rossini. "THU0434 Predictors of long-term glucocorticoid therapy in polymyalgia rheumatica: discontinuation is more common for patients treated with aminobisphosphonates." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Aminobisphosphonate' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography